Loading company…
Thryv Therapeutics develops selective inhibitors for long QT syndrome, heart failure, and atrial fibrillation.
Thryv Therapeutics develops medicines using potent, selective inhibitors of Serum Glucocorticoid inducible Kinase. Founded in 2019, the company is based in Montreal, Canada, and is at the Series A stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in